BLLN
BillionToOne, Inc.
Key Financials
Gross Profit
$208.5M
↑ 157.6%
Operating Income
$16.0M
↑ 134.0%
Revenue
$305.1M
↑ 100.0%
Net Income
$7.5M
↑ 117.9%
EPS (Diluted)
$0.14
↑ 103.4%
Total Assets
$632.7M
↑ 109.4%
Shareholders' Equity
$480.1M
↑ 290.8%
Cash & Equivalents
$496.0M
↑ 159.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-K | 3/11/2026 | View on SEC |
| 8-K | 3/4/2026 | View on SEC |
| SCHEDULE 13G | 2/17/2026 | View on SEC |
| SCHEDULE 13G | 2/17/2026 | View on SEC |
| SCHEDULE 13G | 2/13/2026 | View on SEC |
| SCHEDULE 13D | 1/20/2026 | View on SEC |
| 4 | 1/20/2026 | View on SEC |
| 3 | 1/20/2026 | View on SEC |
| 8-K | 1/12/2026 | View on SEC |
| 4 | 1/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BLLN |
| Company Name | BillionToOne, Inc. |
| CIK | 2070849 |
| Sector | Services-Medical Laboratories |
| Industry | Non-accelerated filer Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-460-2551 |